



Universiteit
Leiden
The Netherlands

The immune divide: factors influencing immune variation and differences in vaccine responses

Pyuza, J.J.

Citation

Pyuza, J. J. (2025, November 25). *The immune divide: factors influencing immune variation and differences in vaccine responses*. Retrieved from <https://hdl.handle.net/1887/4283867>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4283867>

Note: To cite this publication please use the final published version (if applicable).

1

Chapter 1

General introduction and thesis outline

Introduction

Vaccines represent a significant milestone in modern medicine, second only to clean water and sanitation for reducing morbidity and mortality from infectious diseases[1-3]. However, immune systems vary significantly across populations, resulting in variations in immune response to vaccines[4-8]. Understanding the factors associated with immune variability that led to differences in vaccine responses is critical to addressing poor vaccine efficacy in populations that need it the most. Leveraging advanced single-cell technologies such as Mass Cytometry (CyTOF)[9], conventional flow cytometry [10], 16S rRNA Sequencing[11], other omics technologies[12-14], and advanced data analysis, researchers have been able to dissect the factors driving immune variability across different populations. These tools have also shed light on the underlying factors linked to variations in immune responses to vaccines as further demonstrated below.

Genetics, sex and age

Immune variability is partly driven by genetic background [4, 7, 15-18]. Human genetic factors such as HLA polymorphisms[19, 20], PRRs [21, 22], and cytokine production genes[21], are linked to vaccine response variability. For example, individuals with certain HLA haplotypes show higher immune responses to HIV [23] and malaria vaccines[24, 25]. Beyond genetics, sex differences significantly impacts immune variation [26, 27], with women typically generating higher antibody titers to most of the vaccines than men[28-30]. However, gender roles in low- and middle-income countries (LMICs) can confound these differences[33]. Age also modulates immune variability, especially at the extremes of life in infants[34], and the elderly due to less developed or reduced activity of the immune system[35-38]. This consequently causes poor vaccine responses in both age groups[39-42]. It is important to note that age is also influenced by extrinsic factors, including environmental influences, which play a role in immune-biological ageing.

Geographical location and seasons

Non-genetic factors often play a larger role, particularly in adaptive immunity, which is more susceptible to environmental influences[4, 7, 15-18]. Immune profiles vary between HICs and LMICs [43-45], and between rural and urban settings[44, 45]. Similarly, immunogenicity to

vaccines differs in similar patterns, for example, vaccine immunogenicity was higher in the UK and Switzerland compared to Senegal, Malawi, and Uganda[46, 47]. Higher immunogenicity to tetanus and influenza vaccines has been also observed in semi-urban compared to their rural counterparts[48, 49]. Evidence suggests that dry and wet seasons influence immunological differences[50], higher antibody levels have been observed for vaccines administered during wet seasons compared to dry seasons in some populations[51, 52].

Infections/Pathogen factors

Pathogens significantly shape immune system function, contributing to immune variation. For instance, cytomegalovirus (CMV), which infects over 90% of individuals in LMICs, is strongly linked to immune variation and impairs vaccine responses, such as those for Ebola[53-55]. Similarly, *Schistosoma* infection skews the immune system [44, 56] and is associated with reducing vaccine efficacy for hepatitis B[57], BCG [58], TT[59], and measles vaccines[60]. Furthermore, malaria, endemic in many tropical regions, is linked to immune variation [61-64] and is associated with lower antibody responses to vaccines like measles[65], tetanus[66], *Haemophilus influenzae* type B, *Salmonella typhi*, and *Neisseria meningitidis*[67]. Ectoparasites such as tsetse flies, kissing bugs, fleas, and ticks, can also drive immune variations through compounds they inject, though their impact on vaccines remains uncertain [68, 69]. Additionally, chronic infections such as HIV, tuberculosis, and hepatitis C virus (HCV) also contribute to immune variation and affect vaccine efficacy/immunogenicity [70].

Lifestyle and socioeconomic factors

Lifestyle factors such as smoking, exercise, sleeping and alcohol consumption are linked to immune variation[71]. Cigarette smoking is known to affect both innate- and adaptive immunity[72], leading to increased leukocytes and reduced NK cell numbers, serum immunoglobulin levels and poor vaccine efficacy/immunogenicity[73-75]. While socioeconomic status (SES) is complex and intertwined with other factors, making it difficult to isolate, low SES is linked to higher exposure to pathogens, poorer nutrition, and limited access to healthcare, all of which contribute to immune variation[76]. This, in turn, has been linked to reduced vaccine efficacy as seen with vaccines like polio [77] and oral rotavirus [78, 79]. Diet is vital for immune function, fueling both innate and adaptive systems[80, 81].

Malnutrition is linked to poor disease control and reduced vaccine responses[82]. Additionally, essential nutrients like iron and vitamin D also influence immune variation and vaccine efficacy based on their availability.

Microbiome

The microbiome significantly influences immune system variation through interactions with immune cells, affecting their development and regulatory functions[83]. Variations in microbiome composition are linked to differences in immune profiles and immune response to vaccines [84, 85]. Additionally, specific microbial populations can induce distinct immune profiles, underscoring the role of personalized microbiota in shaping immune variation[86, 87]. Although not always the case, individuals with similar microbiomes, regardless of location, tend to have comparable vaccine responses, as seen in infants from Ghana, Pakistan, and the Netherlands[88, 89]. Certain bacteria, like *Bifidobacterium longum*, enhance vaccine responses to tetanus, BCG, and Hepatitis B[90], while others, like *Proteobacteria*, are negatively associated with vaccine efficacy[40]. Factors such as delivery method at birth, diet, infections, and medications also shape microbiomes[91].

Pre-existing immunity

Pre-existing immunity can reduce vaccine efficacy. For instance, exposure to non-tuberculous mycobacteria (NTM) has been linked to lower BCG efficacy against *Mycobacterium tuberculosis*[92], similarly, exposure to Malaria has been associated with reduced or no change in antibody levels after administration of malaria vaccines[93]. In the case of yellow fever, prior vaccination can impair the boosting effect of the Yellow Fever vaccine[94], though some flaviviruses, such as dengue, benefit from prior exposure to related viruses [95]. Also, the natural infections or previous vaccinations with Ebola [96] or COVID-19[97, 98] vaccines lead to higher antibody production after subsequent vaccinations. Possibly this is due to differences in vaccine type and mechanism of action of vaccines[99].

Vaccine-related factors

Vaccine factors, such as differences in Yellow Fever vaccine strains (17D-204, 17D-213, and 17DD) used by different countries, can cause variations in vaccine efficacy/immunogenicity[100]. Dosing and schedules vary and can be linked to variations in vaccine efficacy[101][103]. Additionally, adjuvants as seen with influenza[104] and hepatitis B vaccines[105].

Baseline immune status

Finally, baseline immune status is associated with variation in vaccine response. All host factors discussed above can potentially determine the status of baseline immune status(BIS)[106]. BIS has been linked to a diversity of vaccine responses [107-110]. Baseline immune status, both innate and adaptive level, if optimized before vaccination can help improve the vaccine responses.




Figure 1: The factors associated with immune variation and differences in immune response to vaccines.

Potential mechanisms of pathogen-driven vaccine hypo-responsiveness

To move beyond observed associations and understand why vaccines underperform in certain populations, it is essential to explore the underlying immunological mechanisms. While this section enumerates pathogen-associated variations in vaccine efficacy, the mechanistic underpinnings such as immune exhaustion (characterized by sustained expression of PD1, TIM3, CTLA4, and diminished effector function), chronic immune activation marked by CD38+HLA-DR+ cell profiles, skewed T helper cell polarization (favoring regulatory or TH2 over TH1 responses), and structural alterations in lymphoid tissues are further dissected in **Chapter 2**. These immune dysregulations emerge in response to persistent exposure to environmental antigens, microbiome-derived metabolites, and chronic infections, particularly in low-resource settings. **Chapter 2** builds on these observations by examining how these contexts reshape the immune landscape, ultimately compromising vaccine responsiveness through exhaustion, immunosenescence, regulatory dominance, and disrupted antigen presentation.

The scope and aims of this thesis

The overarching aim of this thesis is to investigate how factors such as the microbiota, environment, lifestyle, and baseline immune profiles contribute to variations in vaccine immunogenicity. Focusing on healthy Tanzanian adults, we explore the rural–urban immune divide using high-resolution immune profiling tools such as mass cytometry, conventional flow cytometry and microbiome sequencing(16S rRNA sequencing). To achieve this, we conducted three distinct studies: two cross-sectional studies and one longitudinal cohort study. To ensure methodological rigor and minimize selection and measurement biases, all three studies employed standardized recruitment procedures, eligibility screening, and validated data collection tools. A school based approach, and community-based sensitization campaigns facilitated participant enrollment, and structured questionnaires adapted from previously validated studies used were administered by trained personnel. In the longitudinal study, participants were randomly assigned to vaccinated and control groups to reduce selection bias. In summary the first cross-sectional study focused on evaluating the prevalence and diagnostic accuracy of tools used for diagnosing schistosomiasis in a rural setting. This study involved over 500 school-aged children, providing critical insights into the prevalence and effectiveness of diagnostic methods in resource-limited environments. The second cross-sectional study aimed to compare the immunological profiles of individuals from rural and urban areas, while

identifying factors contributing to these variations. Participants were recruited from four distinct study sites, two rural and two urban, where blood, stool, and urine samples were collected. Detailed questionnaires were used to capture individual lifestyle factors such as socioeconomic status, diet, and environmental exposures, helping to elucidate the intrinsic and extrinsic drivers of immune variation.

The third study, a longitudinal cohort study, followed individuals from two of the selected study sites one rural and one urban. A total of 185 participants were recruited, with an even distribution between rural and urban settings. To examine the factors influencing vaccine response, both groups were administered the yellow fever vaccine. Biological samples (blood, stool, urine) were collected at multiple time points before vaccination, and on days 2, 7, 14, 28, 56, 90, and 178 post-vaccination. Additionally, detailed lifestyle information was gathered through questionnaires, capturing data on socio-economic factors, diet, and other relevant variables. Advanced single-cell technology, such as mass cytometry, helped in dissecting the immune cell profiles at high resolution, while 16S rRNA sequencing provided insights into microbiome composition. This integrative approach allowed for a comprehensive analysis of the intrinsic and extrinsic factors shaping immune variation and vaccine response in Tanzanian adults.

Thesis outline

This thesis is divided into seven chapters, each addressing key aspects of factors shaping immune variation and vaccine response.

The **first chapter** serves as an introduction, we provide an overview of various factors influencing immune system variation and vaccine responses, setting the foundation for this thesis.

In the **second chapter**, we conduct a comprehensive review of immunological factors linked to geographical variations in vaccine response, delving into the mechanisms behind vaccine hypo-responsiveness and global disparities in vaccine efficacy.

In the **third chapter**, we present field and laboratory-based findings on the prevalence of Schistosomiasis among school-aged children in Mwanga District, Tanzania, providing insight into the prevalence of schistosomiasis.

In the **fourth chapter**, we explore the impact of lifestyle factors on cellular immune profiles, focusing on differences between rural and urban populations in Tanzania, and analyze the factors associated with immune profile variations.

In the **fifth chapter**, we examine the association between the innate immune state at baseline and vaccine responses, aiming to gain a deeper understanding of the immunological mechanisms underlying variations in vaccine efficacy. In the **sixth chapter**, we examine differences in gut microbiome composition between rural and urban settings and investigate the associations between gut microbiota and vaccine responses. We also compare vaccine responses between these populations.

In the **final chapter**, we discuss the key findings, synthesize the results, and propose future research directions based on the implications of the study.

Reference:

1. Greenwood, B., *The contribution of vaccination to global health: past, present and future*. Philosophical Transactions of the Royal Society B-Biological Sciences, 2014. **369**(1645).
2. Rappuoli, R., et al., *Vaccines, new opportunities for a new society*. Proceedings of the National Academy of Sciences of the United States of America, 2014. **111**(34): p. 12288-12293.
3. Rodrigues, C.M.C. and S.A. Plotkin, *Impact of Vaccines; Health, Economic and Social Perspectives*. Frontiers in Microbiology, 2020. **11**.
4. Brodin, P., et al., *Variation in the human immune system is largely driven by non-heritable influences*. Cell, 2015. **160**(1-2): p. 37-47.
5. Brodin, P., et al., *Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences*. Cell, 2015. **160**(1-2): p. 37-47.
6. Souquette, A. and P.G. Thomas, *Variation in the basal immune state and implications for disease*. Elife, 2024. **13**.
7. Duffy, D., *Understanding immune variation for improved translational medicine*. Current Opinion in Immunology, 2020. **65**: p. 83-88.
8. Liston, A., E.J. Carr, and M.A. Linterman, *Shaping Variation in the Human Immune System*. Trends Immunol, 2016. **37**(10): p. 637-646.
9. Simoni, Y., et al., *Mass cytometry: a powerful tool for dissecting the immune landscape*. Current Opinion in Immunology, 2018. **51**: p. 187-196.
10. Proserpio, V. and B. Mahata, *Single-cell technologies to study the immune system*. Immunology, 2016. **147**(2): p. 133-140.
11. Johnson, J.S., et al., *Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis*. Nature Communications, 2019. **10**.
12. Baysoy, A., et al., *The technological landscape and applications of single-cell multi-omics*. Nature Reviews Molecular Cell Biology, 2023. **24**(10): p. 695-713.
13. Heumos, L., et al., *Best practices for single-cell analysis across modalities*. Nature Reviews Genetics, 2023. **24**(8): p. 550-572.
14. Wen, L., et al., *Single-cell technologies: From research to application*. Innovation, 2022. **3**(6).
15. Patin, E., et al., *Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors (vol 19, pg 302, 2018)*. Nature Immunology, 2018. **19**(6): p. 645-645.
16. Astle, W.J., et al., *The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease*. Cell, 2016. **167**(5): p. 1415-+.
17. Farber, D.L., N.A. Yudanin, and N.P. Restifo, *Human memory T cells: generation, compartmentalization and homeostasis*. Nature Reviews Immunology, 2014. **14**(1): p. 24-35.
18. Kolaczowska, E. and P. Kubes, *Neutrophil recruitment and function in health and inflammation*. Nature Reviews Immunology, 2013. **13**(3): p. 159-175.
19. Amirzargar, A.A., et al., *HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine*. Iran J Immunol, 2008. **5**(2): p. 92-9.
20. Ovsyannikova, I.G., et al., *Human leukocyte antigen and cytokine receptor*

- gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. *Pediatrics*, 2008. **121**(5): p. E1091-E1099.
21. Randhawa, A.K., et al., *Association of Human TLR1 and TLR6 Deficiency with Altered Immune Responses to BCG Vaccination in South African Infants*. *Plos Pathogens*, 2011. **7**(8).
 22. Moore, C.E., et al., *Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine*. *Clinical and Vaccine Immunology*, 2012. **19**(3): p. 295-303.
 23. Gartland, A.J., et al., *Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial*. *J Virol*, 2014. **88**(15): p. 8242-55.
 24. Reyes, C., et al., *Critical role of HLA-DR β * binding peptides' peripheral flanking residues in fully-protective malaria vaccine development*. *Biochemical and Biophysical Research Communications*, 2017. **489**(3): p. 339-345.
 25. Nielsen, C.M., et al., *RTS,S malaria vaccine efficacy and immunogenicity during challenge is associated with HLA genotype*. *Vaccine*, 2018. **36**(12): p. 1637-1642.
 26. Dunn, S.E., W.A. Perry, and S.L. Klein, *Mechanisms and consequences of sex differences in immune responses*. *Nature Reviews Nephrology*, 2024. **20**(1): p. 37-55.
 27. Oertelt-Prigione, S., *The influence of sex and gender on the immune response*. *Autoimmunity Reviews*, 2012. **11**(6-7): p. A479-A485.
 28. Bayas, J.M., et al., *Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary?* *Epidemiology and Infection*, 2001. **127**(3): p. 451-460.
 29. Klein, S.L., A. Jedlicka, and A. Pekosz, *The Xs and Y of immune responses to viral vaccines (vol 10, pg 338, 2010)*. *Lancet Infectious Diseases*, 2010. **10**(11): p. 740-740.
 30. Hoffmann, J.P., et al., *Sex hormone signaling and regulation of immune function*. *Immunity*, 2023. **56**(11): p. 2472-2491.
 31. Furman, D., et al., *Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination*. *Proceedings of the National Academy of Sciences of the United States of America*, 2014. **111**(2): p. 869-874.
 32. Potluri, T., et al., *Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females (vol 4, 29, 2019)*. *Npj Vaccines*, 2019. **4**.
 33. Drakesmith, H., et al., *Vaccine Efficacy and Iron Deficiency: An Intertwined Pair?* *The Lancet Haematology*, 2021. **8**(9): p. e666-e669.
 34. Belnoue, E., et al., *APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early life bone marrow stromal cells*. *Swiss Medical Weekly*, 2008. **138**: p. 8s-8s.
 35. Panda, A., et al., *Age-Associated Decrease in TLR Function in Primary Human Dendritic Cells Predicts Influenza Vaccine Response*. *Journal of Immunology*, 2010. **184**(5): p. 2518-2527.
 36. Mogilenko, D.A., I. Shchukina, and M.N. Artyomov, *Immune ageing at single-cell*

- resolution. *Nature Reviews Immunology*, 2022. **22**(8): p. 484-498.
37. Frasca, D. and B.B. Blomberg, *Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination*. *Immunity & Ageing*, 2020. **17**(1).
 38. Nipper, A.J., et al., *Diminished antibody response to influenza vaccination is characterized by expansion of an age-associated B-cell population with low PAX5*. *Clinical Immunology*, 2018. **193**: p. 80-87.
 39. Falahi, S. and A. Kenarkoochi, *Host factors and vaccine efficacy: Implications for COVID-19 vaccines*. *Journal of Medical Virology*, 2022. **94**(4): p. 1330-1335.
 40. Zimmermann, P. and N. Curtis, *The influence of the intestinal microbiome on vaccine responses*. *Vaccine*, 2018. **36**(30): p. 4433-4439.
 41. Wolters, B., et al., *Immunogenicity of combined hepatitis A and B vaccine in elderly persons*. *Vaccine*, 2003. **21**(25-26): p. 3623-3628.
 42. McElhaney, J.E., et al., *The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines*. *Vaccine*, 2012. **30**(12): p. 2060-2067.
 43. Labuda, L.A., et al., *A Praziquantel Treatment Study of Immune and Transcriptome Profiles in -Infected Gabonese Schoolchildren*. *Journal of Infectious Diseases*, 2020. **222**(12): p. 2103-2113.
 44. de Ruiter, K., et al., *Helminth infections drive heterogeneity in human type 2 and regulatory cells*. *Science Translational Medicine*, 2020. **12**(524).
 45. Mbow, M., et al., *Changes in immunological profile as a function of urbanization and lifestyle*. *Immunology*, 2014. **143**(4): p. 569-577.
 46. Black, G.F., et al., *BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies*. *Lancet*, 2002. **359**(9315): p. 1393-1401.
 47. Muyanja, E., et al., *Immune activation alters cellular and humoral responses to yellow fever 17D vaccine (vol 124, pg 3147, 2014)*. *Journal of Clinical Investigation*, 2014. **124**(10): p. 4669-4669.
 48. van Riet, E., et al., *Cellular and humoral responses to tetanus vaccination in gabonese children*. *Vaccine*, 2008. **26**(29-30): p. 3690-3695.
 49. van Riet, E., et al., *Cellular and humoral responses to influenza in Gabonese children living in rural and semi-urban areas*. *Journal of Infectious Diseases*, 2007. **196**(11): p. 1671-1678.
 50. Temba, G.S., et al., *Urban living in healthy Tanzanians is associated with an inflammatory status driven by dietary and metabolic changes*. *Nature Immunology*, 2021. **22**(3): p. 287-+.
 51. Miles, D.J.C., et al., *Effects of antenatal and postnatal environments on CD4 T-cell responses to BCG in healthy infants in the Gambia*. *Clinical and Vaccine Immunology*, 2008. **15**(6): p. 995-1002.
 52. Abreu, T.C., et al., *Association between season of vaccination and antibody levels against infectious diseases*. *Epidemiology and Infection*, 2020. **148**.

53. Griffiths, P. and M. Reeves, *Pathogenesis of human cytomegalovirus in the immunocompromised host*. Nature Reviews Microbiology, 2021. **19**(12): p. 759-773.
54. Sharpe, H.R., et al., *CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination*. Jci Insight, 2022. **7**(6).
55. Bowyer, G., et al., *Reduced Ebola vaccine responses in CMV young adults is associated with expansion of CD57 KLRG1 T cells*. Journal of Experimental Medicine, 2020. **217**(7).
56. Gazzinelli-Guimaraes, P.H. and T.B. Nutman, *Helminth parasites and immune regulation*. F1000Res, 2018. **7**.
57. Muir, R., et al., *infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses*. Plos Neglected Tropical Diseases, 2023. **17**(7).
58. Elias, D., et al., *infection reduces the protective efficacy of BCG vaccination against virulent*. Vaccine, 2005. **23**(11): p. 1326-1334.
59. Sabin, E.A., et al., *Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni*. Journal of Infectious Diseases, 1996. **173**(1): p. 269-272.
60. Twayongyere, R., et al., *Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles catch-up immunisation in pre-school children: A randomised trial*. Plos Neglected Tropical Diseases, 2019. **13**(2).
61. de Jong, S.E., et al., *Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity*. Nature Immunology, 2021. **22**(5): p. 654-+.
62. Portugal, S., et al., *Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function*. Elife, 2015. **4**.
63. Sundling, C., et al., *B cell profiling in malaria reveals expansion and remodeling of CD11c B cell subsets*. Jci Insight, 2019. **4**(9).
64. Weiss, G.E., et al., *Atypical Memory B Cells Are Greatly Expanded in Individuals Living in a Malaria-Endemic Area*. Journal of Immunology, 2009. **183**(3): p. 2176-2182.
65. Kizito, D., et al., *Factors affecting the infant antibody response to measles immunisation in Entebbe-Uganda*. Bmc Public Health, 2013. **13**.
66. Elliott, A.M., et al., *Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation*. Vaccine, 2010. **29**(2): p. 247-55.
67. Williamson, W.A. and B.M. Greenwood, *Impairment of the immune response to vaccination after acute malaria*. Lancet, 1978. **1**(8078): p. 1328-9.
68. Wikel, S.K., *Modulation of the host immune system by ectoparasitic arthropods - Blood-feeding and tissue-dwelling arthropods manipulate host defenses to their advantage*. Bioscience, 1999. **49**(4): p. 311-320.
69. Wilson, A.D., *Immune responses to ectoparasites of horses, with a focus on insect bite hypersensitivity*. Parasite Immunology, 2014. **36**(11): p. 558-570.
70. Vimali, J., et al., *Chronic Viral Infection Compromises the Quality of Circulating Mucosal-Associated Invariant T Cells and Follicular T Helper Cells via*

- Expression of Inhibitory Receptors*. Frontiers in Bioscience-Landmark, 2024. **29**(3).
71. Linfen Guo, Y.H., Jing He, Deng Li, Wei Li, Haitao Xiao, Xuewen Xu, and Y.Z.R. Wang, *Associations of lifestyle characteristics with circulating immune markers in the general population based on NHANES 1999 to 2014*. Scientific Reports | 2024.
 72. Sopori, M., *Effects of cigarette smoke on the immune system*. Nature Reviews Immunology, 2002. **2**(5): p. 372-377.
 73. Ferson, M., et al., *Low Natural Killer-Cell Activity and Immunoglobulin Levels Associated with Smoking in Human-Subjects*. International Journal of Cancer, 1979. **23**(5): p. 603-609.
 74. Jung, Y.S., et al., *Impact of Smoking on Human Natural Killer Cell Activity: A Large Cohort Study*. Journal of Cancer Prevention, 2020. **25**(1): p. 13-20.
 75. Saint-André, V., et al., *Smoking changes adaptive immunity with persistent effects*. Nature, 2024. **626**(8000).
 76. Azad, M.B., et al., *Influence of Socioeconomic Status Trajectories on Innate Immune Responsiveness in Children*. Plos One, 2012. **7**(6).
 77. Grassly, N.C., et al., *New strategies for the elimination of polio from India*. Science, 2006. **314**(5802): p. 1150-1153.
 78. Patel, M., et al., *Oral Rotavirus Vaccines: How Well Will They Work Where They Are Needed Most?* Journal of Infectious Diseases, 2009. **200**: p. S39-S48.
 79. Zaman, K., et al., *Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial*. Lancet, 2010. **376**(9741): p. 615-623.
 80. Newsholme, P., *Cellular and metabolic mechanisms of nutrient actions in immune function*. Nutrition & Diabetes, 2021. **11**(1).
 81. Tourkochristou, E., C. Triantos, and A. Mouzaki, *The Influence of Nutritional Factors on Immunological Outcomes*. Frontiers in Immunology, 2021. **12**.
 82. Cunningham-Rundles, S., D.F. McNeely, and A. Moon, *Mechanisms of nutrient modulation of the immune response*. Journal of Allergy and Clinical Immunology, 2005. **115**(6): p. 1119-1128.
 83. Wiertsema, S.P., et al., *The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies*. Nutrients, 2021. **13**(3).
 84. Vlasova, A.N., et al., *How the gut microbiome regulates host immune responses to viral vaccines*. Current Opinion in Virology, 2019. **37**: p. 16-25.
 85. Ciabattini, A., et al., *Role of the Microbiota in the Modulation of Vaccine Immune Responses*. Frontiers in Microbiology, 2019. **10**.
 86. Jordan, C.K.I. and T.B. Clarke, *How does the microbiota control systemic innate immunity?* Trends in Immunology, 2024. **45**(2): p. 94-102.
 87. Round, J.L. and S.K. Mazmanian, *The gut microbiota shapes intestinal immune responses during health and disease (vol 9, pg 313, 2009)*. Nature Reviews Immunology, 2009. **9**(8): p. 600-600.

88. Harris, V.C., et al., *Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana*. *Journal of Infectious Diseases*, 2017. **215**(1): p. 34-41.
89. Harris, V., et al., *Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan*. *Gut Microbes*, 2018. **9**(2): p. 93-101.
90. Huda, M.N., et al., *Bifidobacterium Abundance in Early Infancy and Vaccine Response at 2 Years of Age*. *Pediatrics*, 2019. **143**(2).
91. Jeong, S., Factors Influencing Development of the Infant Microbiota: From Prenatal Period to Early Infancy. *Clinical and Experimental Pediatrics*, 2022. **65**(9): p. 439-447.
92. Poyntz, H.C., et al., *Non-tuberculous mycobacteria have diverse effects on BCG efficacy against*. *Tuberculosis*, 2014. **94**(3): p. 226-237.
93. Ubillos, I., et al., *Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children*. *BMC Med*, 2018. **16**(1): p. 197.
94. Bovay, A., et al., *Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies*. *Vaccine*, 2020. **38**(9): p. 2172-2182.
95. Whitehead, S.S., et al., *In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination*. *Plos Neglected Tropical Diseases*, 2017. **11**(5).
96. Koch, T., et al., *Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins*. *Viruses-Basel*, 2020. **12**(9).
97. Angyal, A., et al., *T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study*. *Lancet Microbe*, 2022. **3**(1): p. E21-E31.
98. Tang, J.Y., et al., *Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination*. *Science Immunology*, 2022. **7**(76).
99. Vanaparthi, R., et al., *Review of COVID-19 viral vector-based vaccines and COVID-19 variants*. *Infez Med*, 2021. **29**(3): p. 328-338.
100. Beck, A.S. and A.D.T. Barrett, *Current status and future prospects of yellow fever vaccines*. *Expert Review of Vaccines*, 2015. **14**(11): p. 1479-1492.
101. Hoest, C., et al., *Evaluating Associations Between Vaccine Response and Malnutrition, Gut Function, and Enteric Infections in the MAL-ED Cohort Study: Methods and Challenges*. *Clinical Infectious Diseases*, 2014. **59**: p. S273-S279.
102. Abdala-Torres, T., et al., *Immune response induced by standard and fractional doses of 17DD yellow fever vaccine*. *Npj Vaccines*, 2024. **9**(1).
103. Amirthalingam, G., et al., *Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England (vol 12, 7217, 2021)*. *Nature Communications*, 2022. **13**(1).
104. Khurana, S., et al., *MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to*

- Pandemic Influenza Vaccines*. Science Translational Medicine, 2011. **3**(85).
105. Jacques, P., et al., *The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population*. Vaccine, 2002. **20**(31-32): p. 3644-3649.
 106. Nehar-Belaid, D., et al., *Baseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS*. Seminars in Immunology, 2023. **70**.
 107. Hagan, T., et al., *Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses*. Nature Immunology, 2022. **23**(12): p. 1788-+.
 108. Querec, T.D., et al., *Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans*. Nature Immunology, 2009. **10**(1): p. 116-125.
 109. Tsang, J.S., et al., *Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?* Trends in Immunology, 2020. **41**(6): p. 457-465.
 110. Odak, I., et al., *Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine*. Ebiomedicine, 2024. **99**.